Precision cancer therapy is impacted by oncogene-dependent epigenome remodeling

Abstract The cancer genome provides the blueprint for identifying oncogenic mutations driving tumor growth and these mutant proteins and pathways are the targets for precision cancer therapies. However, many oncogenes are capable of reprogramming the landscape of active portion of the genome, common...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Feng Liu, Paul S. Mischel, Webster K. Cavenee
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Acceso en línea:https://doaj.org/article/8741ff04de824f7585fff1793dbafe1b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Abstract The cancer genome provides the blueprint for identifying oncogenic mutations driving tumor growth and these mutant proteins and pathways are the targets for precision cancer therapies. However, many oncogenes are capable of reprogramming the landscape of active portion of the genome, commonly known as the epigenome. This creates fluidity, and thereby heterogeneity, that demands consideration of this additional layer of complexity for effective therapeutic design and application. Molecular dissection of the epigenome may identify oncogene-induced, actionable vulnerabilities, broadening the spectrum of precision oncology treatments.